Heterologous immunity to Epstein-Barr virus: dissecting the role of cross-reactive CD8 T cells in mediating disease outcome in children, young adults and the elderly

Projektinformationen

EBV HORIZONS

ID Finanzhilfevereinbarung: 219603

Projekt abgeschlossen

Startdatum 1 Mai 2008

Enddatum 30 April 2011

Finanziert unter

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Gesamtkosten € 240 373,81

EU-Beitrag € 240 373,81

Koordiniert durch

CARDIFF UNIVERSITY
United Kingdom